Cellular Immunotherapy in development:
CIM101: Dendritic cells vaccine (Lung Cancer)
First of all, CiMaas is developing a dendritic cell vaccine using its proprietary maturation technology. CiMaas will investigate this therapy in clinical trials for patients with metastatic lung cancer who eligible for treatment with a check point inhibitor.
CIM201: Haploidentical adoptive NK cell therapy (Breast, Multiple Myeloma)
Furthermore, CiMaas is developing a haploidentical NK cell product. CiMaas will investigate this therapy for the treatment of patients with metastasized breast cancer and multiple myeloma.